* Roivant Sciences Ltd ROIV.OQ reported a quarterly
adjusted
loss of 31 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -40 cents. The mean expectation of ten analysts
for the quarter was for a loss of 26 cents per share. Wall
Street expected results to range from -34 cents to -11 cents per
share.
* Revenue fell 87.9% to $4.48 million from a year ago;
analysts
expected $49.22 million.
* Roivant Sciences Ltd's reported EPS for the quarter was a
loss
of 31 cents.
* The company reported a quarterly loss of $230.18 million.
* Roivant Sciences Ltd shares had risen by 2.3% this
quarter and
gained 5.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 9.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Roivant Sciences
Ltd is $17.00
This summary was machine generated from LSEG data November 12 at
01:38 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.26 -0.31 Missed
Jun. 30 2024 -0.32 0.12 Beat
Mar. 31 2024 -0.30 -0.19 Beat
Dec. 31 2023 -0.32 -0.30 Beat